# Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule; correction.
**SUMMARY:**
The Food and Drug Administration (FDA) is correcting a final rule that appeared in the *Federal Register* of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error.
**FOR FURTHER INFORMATION CONTACT:**
Diane Sullivan, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171.
**SUPPLEMENTARY INFORMATION:**
In FR Doc. 2010-8467, appearing on page 19213, in the *Federal Register* of Wednesday, April 14, 2010, the following correction is made:
1. On page 19213, in the third column, the heading “RIN 0910-AF92” is corrected to read “RIN 0910-AF93”.
Dated: September 13, 2010.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.